Search



Search only items with full text availability
Current filters:

Clear current filters  or Add more filters

View Option



Results 1-10 of 64 (Search time: 0.002 seconds).

  Near-absolute expression of the bcl-2 protein identifies a subgroup of stage II breast cancer patients with a most favorable outcome. Results of a clinicopathological study (Journal article)

  Weekly docetaxel in minimally pretreated cancer patients: a dose-escalation study focused on feasibility and cumulative toxicity of long-term administration (Journal article)

  Successful rechallenge with taxanes following prophylactic ketotifen in patients who had developed severe hypersensitivity reactions (Journal article)

  Severe autoimmune hemolytic anemia following fludarabine therapy in a patient with chronic lymphocytic leukemia (Journal article)

  Phase I study of etoposide, cisplatin and irinotecan triplet in patients with advanced-stage small-cell lung cancer (Journal article)

  Phase I trial and pharmacokinetics of the tubulin inhibitor 1069C85--a synthetic agent binding at the colchicine site designed to overcome multidrug resistance (Journal article)

  Phase I trial of weekly irinotecan and paclitaxel combined with carboplatin in patients with advanced cancer: a Hellenic Cooperative Oncology Group Study (Journal article)

  Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group (Journal article)

  Paclitaxel by three-hour infusion and carboplatin in advanced carcinoma of nasopharynx and other sites of the head and neck. A phase II study conducted by the Hellenic Cooperative Oncology Group (Journal article)

  Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group (Journal article)